Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The companyâs lead product candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy. Source
No articles found.
HJLI specializes in developing and manufacturing bioprosthetic medical devices to ...
HJLI specializes in developing and manufacturin...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
We are a clinical-stage biopharmaceutical company focused on improving the lives o...
We are a clinical-stage biopharmaceutical compa...
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology comp...
Amicus Therapeutics (Nasdaq: FOLD) is a global,...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.